What Researchers Did
Researchers presented a case report detailing severe, very late-onset chronic side effects in a patient 26 years after receiving radical chemoradiotherapy for anal canal cancer.
What They Found
A patient treated for stage T3N3M0 anal cancer in 1998 received cumulative doses up to 77.6 Gy, achieving complete disease regression. Fourteen years post-treatment, the patient developed vast fibroatrophy and necrosis of the anus and perineum, leading to sphincter loss. Twenty years after treatment, asymptomatic osteonecrotic foci appeared in the left femur, progressing to symptomatic osteomyelitis by 26 years, despite two courses of hyperbaric oxygen treatment for the soft tissue issues.
What This Means for Canadian Patients
This case highlights that Canadian anal cancer survivors may experience severe, very late-onset side effects from chemoradiotherapy, even decades after successful treatment. It underscores the importance of long-term follow-up and awareness among healthcare providers for potential chronic complications like fibroatrophy, necrosis, and osteonecrosis in these patients.
Canadian Relevance
No direct Canadian connection identified. Covers a Health Canada-recognized indication (osteoradionecrosis).
Study Limitations
As a single case report, this study's findings may not be generalizable to all patients undergoing similar treatments for anal canal cancer.